Summary of Study ST003029
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001882. The data can be accessed directly via it's Project DOI: 10.21228/M8FQ52 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST003029 |
| Study Title | Estrogen-mediated inhibition of purine metabolism and cell cycle arrest as a novel therapeutic approach in colorectal cancer cells |
| Study Summary | Purine metabolism is upregulated in various cancers including colorectal cancer (CRC). While previous research has elucidated the role of Estrogen (E2) in metabolism remodeling and ATP production, its effects on purine metabolism remained unexplored. This study investigates the impact of E2 signalling on purine metabolism in CRC cells. We demonstrate, for the first time, a protective effect of E2 on CRC cells by targeting the purine synthesis pathway through its receptor estrogen receptor α (ERα). A full metabolomic profiling, next generation sequencing (NGS) and integrated OMICS were conducted for HCT-116 cells treated with E2 with and without silencing ERα. Our results revealed an enrichment of the purine metabolic pathway, with 27 genes in the de novo purine synthesis pathway downregulated in E2-treated CRC cells. Besides, E2-induced DNA damage, cell cycle arrest, and apoptosis are ERα-dependent. Our findings suggest potential therapeutic avenues for CRC treatment through antimetabolites targeting purine synthesis, as E2 treatment reduces the expression of relevant metabolites. |
| Institute | Sharjah Institute for Medical Research |
| Last Name | Facility |
| First Name | Core |
| Address | M32, SIMR, College of Pharmacy, Health Sciences, University of Sharjah, Sharjah, UAE, Sharjah, 000, United Arab Emirates |
| tims-tof@sharjah.ac.ae | |
| Phone | +971 6 5057656 |
| Submit Date | 2023-11-29 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | d |
| Analysis Type Detail | LC-MS |
| Release Date | 2024-05-31 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Combined analysis:
| Analysis ID | AN004966 |
|---|---|
| Analysis type | MS |
| Chromatography type | Reversed phase |
| Chromatography system | Bruker Elute |
| Column | Hamilton® Intensity Solo 2 C18 column (2.1 × 100 mm, 1.8 µm) |
| MS Type | ESI |
| MS instrument type | QTOF |
| MS instrument name | Bruker timsTOF |
| Ion Mode | POSITIVE |
| Units | AU |
Chromatography:
| Chromatography ID: | CH003748 |
| Chromatography Summary: | An ultra-high-performance liquid chromatography system; Elute UHPLC (Bruker Daltonik GmbH, Bremen, Germany) . 10 µL aliquot of the sample was injected and the separation was performed on a Hamilton® Intensity Solo C18 column (2.1 × 100 mm, 1.8 µm) (Bruker Daltonik) in a column oven temperature set at 35 ◦C , using solvent A (0.1% formic acid in deionized Water) and solvent B (0.1% formic acid in acetonitrile) with the following gradient elution mode: 0 to 2 min, 1% B; 2 to 17 min, 1–99% B; 17 to 20 min, 99% B; 20 to 20.1 min, 99–1% B; 20.1 to 30 min, 1% B. The flow rate was 0.25 mL/min from 0 to 20 min, 0.35 mL/min from 20 min to 28.3 min, and 0.25 mL/min from 28.3 to 30 min. |
| Instrument Name: | Bruker Elute |
| Column Name: | Hamilton® Intensity Solo 2 C18 column (2.1 × 100 mm, 1.8 µm) |
| Column Temperature: | 35◦C |
| Flow Gradient: | gradient elution mode: 0 to 2 min, 1% B; 2 to 17 min, 1–99% B; 17 to 20 min, 99% B; 20 to 20.1 min, 99–1% B; 20.1 to 30 min, 1% B. |
| Flow Rate: | The flow rate was 0.25 mL/min from 0 to 20 min, 0.35 mL/min from 20 min to 28.3 min, and 0.25 mL/min from 28.3 to 30 min. |
| Solvent A: | Water (0.1% Formic Acid) |
| Solvent B: | ACN (0.1% Formic Acid) |
| Chromatography Type: | Reversed phase |
